Related Experiment Video
Updated: Mar 19, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier
Jürgen G Okun1, Hongying Gan-Schreier2, Tawfeq Ben-Omran3
1Department of General Pediatrics, Division of Inherited Metabolic Diseases, University Children's Hospital, Heidelberg, Germany. juergen.okun@med.uni-heidelberg.de.
Insights
Early detection of classical homocystinuria (HCU) is crucial. A new two-tier newborn screening strategy using methionine to phenylalanine ratio and homocysteine levels demonstrates 100% accuracy in identifying HCU cases.
Area of Science:
- Biochemistry
- Genetics
- Public Health
Background:
- Classical homocystinuria (HCU) is a genetic disorder treatable with early intervention.
- Existing newborn screening methods require optimization for HCU detection.
Purpose of the Study:
- To develop and validate a cost-effective two-tier strategy for newborn screening of HCU.
- To improve the efficiency and accuracy of HCU detection in neonates.
Main Methods:
- Reevaluation of a large newborn screening dataset (125,047 neonates) from Qatar.
- Analysis included homocysteine (Hcy), methionine (Met), and Met to phenylalanine (Phe) ratio.
- Cross-validation with international newborn screening programs.
Main Results:
- The Met to Phe ratio effectively screened out approximately 90% of normal samples in the first tier.
- Only 10% of samples required a second-tier Hcy measurement.
- The strategy achieved 100% sensitivity and specificity in HCU screening.
Conclusions:
- A two-tier algorithm utilizing Met to Phe ratio followed by Hcy measurement is highly effective for HCU newborn screening.
- This optimized strategy enhances diagnostic accuracy while reducing laboratory workload.
- The findings support the implementation of this improved screening protocol globally.
Background:
In classical homocystinuria (HCU, MIM# 236200) due to the deficiency of cystathionine β-synthase (EC 4.2.1.22) there is a clear evidence for the success of early treatment. The aim of this study was to develop and evaluate a two-tier strategy for HCU newborn screening.
Methods:
We reevaluated data from our newborn screening programme for Qatar in a total number of 125,047 neonates including 30 confirmed HCU patients. Our hitherto existing screening strategy includes homocysteine (Hcy) measurements in every child, resulting in a unique dataset for evaluation of two-tier strategies. Reevaluation included methionine (Met) levels, Met to phenylalanine (Phe) ratio, and Hcy. Four HCU cases identified after database closure were also included in the evaluation. In addition, dried blood spot samples selected by Met values >P97 in the newborn screening programs in Austria, Australia, the Netherlands, and Taiwan were analyzed for Hcy.
Results:
Met to Phe ratio was found to be more effective for first sieve than Met, sorting out nearly 90% of normal samples. Only 10% of the samples would have to be processed by second-tier measurement of Hcy in dried blood spots. As no patient with HCU was found neither in the samples investigated for HCU, nor by clinical diagnosis in the other countries, the generalization of our two-tier strategy could only be tested indirectly.
Conclusion:
The finally derived two-tier algorithm using Met to Phe ratio as first- and Hcy as second-tier requires 10% first-tier positives to be transferred to Hcy measurement, resulting in 100% sensitivity and specificity in HCU newborn screening.
More Related Videos
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pedigree Analysis
Inborn Errors of Metabolism
Automated Microbial Diagnostics
Pharmacokinetics in Pediatric Patients: Drug Metabolism

